MDT-AP-3056
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 14
- sex
- F
- new_clusters
- S2
- umap1_2d
- 0.057292806
- umap2_2d
- -9.638533887
- umap1_3d
- -4.024752613
- umap2_3d
- -1.289119178
- umap3_3d
- 5.838037043
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.480
- ALLOGRAFT_REJECTION+0.430
- INTERFERON_ALPHA_RESPONSE+0.410
- E2F_TARGETS+0.400
- PROTEIN_SECRETION+0.400
- G2M_CHECKPOINT+0.390
- INFLAMMATORY_RESPONSE+0.390
- UV_RESPONSE_DN+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- MYC_TARGETS_V1+0.340
Top 10 suppressed
- ADIPOGENESIS-0.240
- FATTY_ACID_METABOLISM-0.220
- KRAS_SIGNALING_DN-0.220
- MYOGENESIS-0.210
- NOTCH_SIGNALING-0.150
- XENOBIOTIC_METABOLISM-0.150
- OXIDATIVE_PHOSPHORYLATION-0.140
- ANGIOGENESIS-0.120
- COAGULATION-0.110
- PEROXISOME-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3281 | Med | Medulloblastoma | 0.860 |
| 2 | MNG1210 | — | — | 0.859 |
| 3 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.859 |
| 4 | TCGA-BT-A3PJ-01A-21R-A220-07 | — | — | 0.852 |
| 5 | MNG766 | — | — | 0.850 |
| 6 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.846 |
| 7 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.837 |
| 8 | TCGA-XF-AAN5-01A-11R-A42T-07 | — | — | 0.835 |
| 9 | SRR934737 | — | — | 0.834 |
| 10 | TCGA-77-A5GH-01A-11R-A27Q-07 | — | cohortSQ1 | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.430 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |